Find daily information on the evolution of the Coronavirus Covid-19 epidemic, as well as advice and measures taken by the government.
|
The PasseportSanté team is working to provide you with reliable and up-to-date information on the coronavirus. To find out more, find:
|
National education: around 8,000 students infected this week
This week, 7,776 students were reportedly infected, as well as 1,020 staff members. In total, 23 establishments are currently closed out of 64,500 and 135 classes out of 528,000.
Beginning of a vaccination “end of December, beginning of January”?
Agnès Pannier-Runacher, Minister in charge of industry, indicated that the vaccination campaign could start soon: “ We will be ready at the end of December, the beginning of January “. France is currently awaiting authorizations and vaccines.
Germany: More than a million Covid cases
The country now has more than a million cases tested positive for Covid-19 since the start of the pandemic. According to the Robert Koch health watch institute, 1,006,394 patients are officially declared, or 22,806 more in 24 hours. The death toll stands at 15,586, or 426 more in one day.
Decrease in intensive care admissions
According to data from Public Health France published yesterday, the total number of patients in intensive care is 4,006 (against 4,136 the day before), with 192 new admissions in 24 hours. We note a slight decrease since Wednesday, there were 258 entries. Regarding hospitalizations, France recorded 29,282 patients still hospitalized on Thursday, against 29,944 the day before. As a reminder, the peak in mid-November was around 33,000.
India: the country will produce more than 100 million doses of the Russian vaccine
An agreement has been reached between the Russian Sovereign Fund (RDIF) and the Indian pharmaceutical group Hetero. Production of more than 100 million doses of Russian vaccine Sputnik V is expected to begin ” early 2021 Says RDIF, which funded the development of the vaccine.
Vaccine: AstraZeneca requires “an additional study”
The managing director of the British laboratory, which developed the AstraZeneca vaccine with the University of Oxford, said in a press release that the vaccine developed requires ” an additional study “. The UK government has requested an evaluation of the vaccine from the Medicines Health Regulatory Authority.
